Merck & Co has opened a new $400 million bulk chemical manufacturingplant in Singapore, which will produce active ingredients for the company's asthma treatments, such as its leukotriene antagonist Singulair (montelukast) and for arthritis drugs like Vioxx (rofecoxib), according to the Associated Press.
About 160 people will be employed at the new facility, said Singapore's Deputy Prime Minister Tony Tan, who claimed that the plant will help Singapore's push to develop its biomedical science industry.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze